JANX
Janux Therapeutics Inc

1,679
Mkt Cap
$792.48M
Volume
813,596.00
52W High
$36.25
52W Low
$12.12
PE Ratio
-7.81
JANX Fundamentals
Price
$13.08
Prev Close
$13.42
Open
$13.29
50D MA
$13.94
Beta
1.50
Avg. Volume
1.71M
EPS (Annual)
-$1.28
P/B
0.81
Rev/Employee
$130,716.05
$1,875.71
Loading...
Loading...
News
all
press releases
Readystate Asset Management LP Boosts Stock Holdings in Janux Therapeutics, Inc. $JANX
Readystate Asset Management LP lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 38.0% in the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been...
Business Wire·5d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low - Should You Sell?
Janux Therapeutics (NASDAQ:JANX) Hits New 52-Week Low - Time to Sell...
MarketBeat·16d ago
News Placeholder
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in Janux Therapeutics (JANX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·19d ago
News Placeholder
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fifteen research firms that are currently covering the stock...
MarketBeat·21d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Should You Sell?
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down - Here's Why...
MarketBeat·26d ago
News Placeholder
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor...
Business Wire·27d ago
News Placeholder
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.
Zacks·30d ago
News Placeholder
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading Volume - Here's Why
Janux Therapeutics (NASDAQ:JANX) Sees Unusually-High Trading Volume - Still a Buy...
MarketBeat·1mo ago
News Placeholder
Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.read more...
Benzinga·1mo ago
<
1
2
...
>

Latest JANX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.